← Leaderboards
Andrew A. Raubitschek
City Of Hope National Medical Center
$10,642,515
Attributed
$11,388,937
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–15$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$40,356,469 · 12
By mechanism
P01$31,822,312 · 7
P50$7,538,928 · 4
R44$995,229 · 1
Top collaborators
- David Morris Colcher2 shared
- Paul Yazaki2 shared
- David T Ho1 shared
- Bradley T Wyman1 shared
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTumorClinical TrialsAntibodiesMalignant NeoplasmsDesignDoseImmunotherapyT-LymphocyteGrantClinical ResearchImmunotherapeutic AgentReagentRadiotracerCitiesRadioimmunotherapyImmunologicsIl2 GeneProtocols DocumentationInsightCorrelative StudyMolecularMonoclonal AntibodyLymphoma
Grant awards (46)
CD19-Specific Central Memory T Cell Adoptive Immunotherapy for Non-Hodgkin Lymphoma$1,038,189
P50 · FY2015 · CA · contact PI
Humanized Anti-CD20-IL2 for the Treatment of CD20 Positive Lymphomas$224,642
P50 · FY2015 · CA · contact PI
CD19-Specific Central Memory T Cell Adoptive Immunotherapy for Non-Hodgkin Lymphoma$1,152,253
P50 · FY2014 · CA · contact PI
Humanized Anti-CD20-IL2 for the Treatment of CD20 Positive Lymphomas$197,793
P50 · FY2014 · CA · contact PI
Anit-CD25 Radioimmunotherapy for Hodgkin Lymphoma$1,284,135
P50 · FY2013 · CA · contact PI
Humanized Anti-CD20-IL2 for the Treatment of CD20 Positive Lymphomas$275,992
P50 · FY2013 · CA · contact PI
Anit-CD25 Radioimmunotherapy for Hodgkin Lymphoma$1,098,070
P50 · FY2012 · CA · contact PI
Clinical Production and IND enabling Studies for PSCA Minibody Imaging in Pancrea$923,853
R44 · FY2012 · CA
CEA TARGETED IMMUNOTHERAPEUTICS$471,632
P01 · FY2012 · CA · contact PI
Humanized Anti-CD20-IL2 for the Treatment of CD20 Positive Lymphomas$235,438
P50 · FY2012 · CA · contact PI
Administration$93,425
P01 · FY2012 · CA · contact PI
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors$1,745,671
P01 · FY2011 · CA · contact PI
CEA TARGETED IMMUNOTHERAPEUTICS$379,655
P01 · FY2011 · CA · contact PI
Clinical Production and IND enabling Studies for PSCA Minibody Imaging in Pancrea$71,376
R44 · FY2011 · CA
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors$3,057,784
P01 · FY2010 · CA · contact PI
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors$1,999,788
P01 · FY2010 · CA · contact PI
CEA TARGETED IMMUNOTHERAPEUTICS$440,896
P01 · FY2010 · CA · contact PI
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors$3,001,468
P01 · FY2009 · CA · contact PI
CEA TARGETED IMMUNOTHERAPEUTICS$432,259
P01 · FY2009 · CA · contact PI
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors$2,916,216
P01 · FY2008 · CA · contact PI
CEA TARGETED IMMUNOTHERAPEUTICS$419,458
P01 · FY2008 · CA · contact PI
Molecularly Engineered Constructs for anti-CD20 Directed Therapeutics$340,858
P50 · FY2008 · CA · contact PI
Anti-CD30 Radioimmunotherapy of Hodgkin's Lymphoma & CD30+ NonHodgkin's Lymphoma$138,679
P50 · FY2008 · CA · contact PI
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors$2,922,793
P01 · FY2007 · CA · contact PI
CEA TARGETED IMMUNOTHERAPEUTICS$413,331
P01 · FY2007 · CA · contact PI
Molecularly Engineered Constructs for anti-CD20 Directed Therapeutics$329,558
P50 · FY2007 · CA · contact PI
Anti-CD30 Radioimmunotherapy of Hodgkin's Lymphoma & CD30+ NonHodgkin's Lymphoma$205,780
P50 · FY2007 · CA · contact PI
ADMINISTRATION$47,627
P01 · FY2007 · CA · contact PI
Constructs for anti-CD20 Directed Therapeutics$178,887
P50 · FY2006 · CA · contact PI
Anti-CD30 Radioimmunotherapy of Lymphoma$151,784
P50 · FY2006 · CA · contact PI
Bioengineered Antibodies in Cancer Imaging and Therapy$2,865,482
P01 · FY2005 · CA
Constructs for anti-CD20 Directed Therapeutics$173,322
P50 · FY2005 · CA
Anti-CD30 Radioimmunotherapy of Lymphoma$154,849
P50 · FY2005 · CA
Bioengineered Antibodies in Cancer Imaging and Therapy$2,849,003
P01 · FY2004 · CA
Anti-CD30 Radioimmunotherapy of Lymphoma$190,770
P50 · FY2004 · CA
Constructs for anti-CD20 Directed Therapeutics$167,929
P50 · FY2004 · CA
Bioengineered Antibodies in Cancer Imaging and Therapy$2,500,917
P01 · FY2003 · CA
Bioengineered Antibodies in Cancer Imaging and Therapy$2,403,727
P01 · FY2002 · CA
CORE--RADIOPHARMACY$0
P01 · FY2002 · CA
CORE--RADIOIMMUNOTHERAPY$0
P01 · FY2002 · CA
BIOENGINEERED ANTIBODIES IN CANCER IMAGING AND THERAPY$728,162
P01 · FY2001 · CA
CORE--RADIOPHARMACY$0
P01 · FY2001 · CA
CORE--RADIOIMMUNOTHERAPY$0
P01 · FY2001 · CA
BIOENGINEERED ANTIBODIES IN CANCER IMAGING AND THERAPY$1,976,521
P01 · FY2000 · CA
CORE--RADIOPHARMACY$156,497
P01 · FY2000 · CA
CORE--RADIOIMMUNOTHERAPY$0
P01 · FY2000 · CA